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Abstract
Background: The purpose of this retrospective study was to evaluate the efficacy of incorporating trans-arterial
radioembolization (TARE) with systemic chemotherapy in the treatment of liver-dominant metastatic pancreatic
ductal adenocarcinoma, with the aim of destroying liver metastases and improving patient outcomes.
Methods: We retrospectively evaluated 16 patients with liver-dominant metastatic pancreatic ductal adenocarcinoma
who underwent TARE between February 2012 and August 2015; 15 of these patients also underwent concurrent
systemic chemotherapy. Patient outcomes were assessed using Response Evaluation Criteria In Solid Tumors (RECIST),
Version 1.1 and included disease response, median overall survival from the time of diagnosis of metastatic disease,
and median overall survival following receipt of TARE. Treatment-related adverse events were assessed using Common
Terminology Criteria for Adverse Events (CTCAE), Version 4.03.
Results: The median overall survival from the time of diagnosis of metastatic disease and following receipt of TARE
was 22.0 and 12.5 months, respectively. Overall and liver specific disease response were assessed for 13 patients with
follow-up imaging available at the time of study (range 2–13 weeks post TARE). Four patients (31 %) demonstrated
partial response and five patients (38 %) had stable disease in the liver at follow-up. One patient developed grade 3
elevation of total bilirubin three months post-treatment and another patient developed radiation cholecystitis directly
following TARE. No treatment-related grade 4 or 5 toxicities were seen.
Conclusion: TARE can be safely combined with systemic chemotherapy for the treatment of liver-dominant metastatic
pancreatic cancer. Patient outcomes following this treatment strategy are promising but prospective evaluations are
needed to validate these preliminary findings.
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Background
Pancreatic ductal adenocarcinoma (PDAC) is the fourth
leading cause of cancer-related death in the United States
[1]. In 2015, there are expected to be 48,960 new cases,
and 40,560 deaths from pancreatic adenocarcinoma. The
mortality rate of pancreatic cancer is 98 % worldwide [2]
and continues to rise [3].
The only potentially curative treatment option for
PDAC is surgical resection. However, only 10–20 % of
patients are eligible for resection at presentation [2], and
most of those will eventually relapse following surgery [4].
Over half of all PDAC patients have metastases at pres-
entation. Recent trial findings indicate improved outcomes
for patients with metastatic pancreatic cancer and median
overall survival times of 8.5 – 11 months [5, 6]. However,
population based studies demonstrate continued poor out-
comes in the community, with a median overall survival
time of only 4 months [7]. The estimated 5-year survival
rate for patients with metastatic disease is only 2.4 %.
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Trans-arterial radioembolization (TARE) is a form of
liver-directed brachytherapy for treatment of primary
and secondary liver cancers [8]. Based on the liver’s dual
blood supply, intra-arterial delivery of Yttrium-90 radio-
active particles allows for increased uptake of radioactiv-
ity into tumor tissue compared with normal liver tissue,
which is predominantly supplied by the portal vein.
TARE has been shown to effectively achieve local
control and/or improved survival in various tumor types,
including hepatocellular carcinoma [9, 10], metastatic
colorectal cancer [11, 12], neuroendocrine cancer [13, 14],
cholangiocarcinoma [15, 16] and breast cancer [17, 18].
The poor outcomes of currently available therapy for
metastatic pancreatic cancer combined with the newly
found efficacy of TARE on other types of secondary liver
cancers has led to the incorporation of TARE into the treat-
ment arsenal for this patient population. Here we present
our single center experience in the use of TARE for man-
agement of metastatic pancreatic adenocarcinoma.
Methods
The retrospective study reported in this paper was ap-
proved by the local institutional review board. From
February 2012 to August 2015, 16 patients with liver me-
tastases from pancreatic adenocarcinoma were evaluated
and treated with TARE (SIR-Spheres, Sirtex Medical,
Sydney, Australia) at a single academic institution. All pa-
tients were found to have acceptable performance status
(ECOG < 2), adequate hepatic reserve (defined as total
bilirubin < 3.0 mg/dL and AST/ALT < 5x upper normal
limit), and < 50 % of total liver volume replaced with
tumor.
Prior to TARE, all patients underwent a complete
visceral angiography. In order to reduce the risk of GI
ulceration, coil embolization was performed in selected
vessels at the discretion of the operating interventional
radiologist. With the microcatheter tip at the position of
the planned treatment delivery, a dose of technetium-
99 m microaggregated albumin (99mTc-MAA) was deliv-
ered: 111 MBq and 75 MBq for the right and left lobes,
respectively. The patient then underwent a SPECT scan
to calculate the percentage of lung shunting, and to de-
tect potential gastrointestinal delivery. The planned
treatment dose of resin Yttrium-90 was calculated ac-
cording to patient body surface area. [8] Dose reduction
was performed for high lung shunts as per manufacturer
recommendations.
Yttrium-90 radioembolization was performed 1–2
weeks after the mapping angiogram. Delivery of radi-
ation particles to the right and left lobes was performed
with the microcatheter positioned in the right or left
hepatic artery, respectively. Four patients underwent
lobar treatments in separate sessions spaced 14–56 days
apart. Six patients underwent single session whole liver
treatments in order to minimize their time away from
systemic therapy. In order to minimize potential risks of
gastrointestinal ulceration in patients undergoing whole
liver treatments, the radiation particles were delivered in
a lobar fashion using a “split dose” strategy. Following
treatment, all patients were observed for a 4–6 h period
and then discharged.
Fifteen patients were being treated with concurrent
systemic therapy at the time of TARE. Six patients were
receiving a 5-FU-based regimen; eight were receiving
concurrent gemcitabine-based therapy, and one patient
was receiving Abraxane only. Information regarding the
timing of systemic chemotherapy infusions was available
for 13 patients only. Systemic therapy was stopped on
average 18 days (range 8–50 days) prior to TARE, and
was resumed on average 22 days (range 6–46 days)
after TARE.
Follow-up imaging assessment was carried out two to
six months after the final TARE treatment session. Local
and overall disease response was assessed using RECIST
(v 1.1) guidelines by comparison of each follow up
imaging with the baseline study. Pre and post treatment
laboratory values were retrospectively evaluated to assess
for adverse events as defined by CTCAE v 4.3.
Descriptive statistics were used to summarize patients’
characteristics as well as their treatment parameters.
Kaplan-Meier methodology was used to analyze patients’
survival data. The median overall survival time from
diagnosis of liver metastasis to time of analysis was esti-
mated with its 95 % confidence interval when feasible.
SAS software version 9.3 (SAS Inc., Cary NC) was used
in the data analysis.
Results
Eleven male and five female patients were treated for
liver-dominant metastatic PDAC with Yttrium-90 resin
microspheres directed to the liver. All patients were
treated with at least one line of prior or concurrent
chemotherapy at the time of TARE (range 1–3). One pa-
tient had undergone a pancreaticoduodenectomy prior
to developing metastatic disease. Five patients under-
went SBRT to the primary pancreatic lesion, and one
patient had prior chemoembolization for the treatment
of liver disease.
A summary of baseline patient characteristics is outlined
in Table 1.
Ten patients underwent whole liver treatment and six
underwent single lobe treatment. Six of the 10 patients
undergoing whole liver treatment were treated in a
single session with the lobes treated in a split fashion.
There was an average interval of 28 days (range: 14–57
days) in between treatments for the four patients under-
going lobar treatments. The average doses of Yttrium-90
delivered to the right and left lobes of the liver were
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46.32 Gy (30.24 – 65.10) and 54.44 Gy (32.31 – 86.29),
respectively (Table 2).
Eight of the 16 patients were alive at the time of this
retrospective analysis. The median overall survival from
the time of diagnosis of metastatic disease to time of this
retrospective analysis was 22 months (range: 11 – 50)
(Fig. 1a). The median time of survival from TARE is
12.5 months (range: 4 – not reached,) (Fig. 1b). The
estimated survival rate from diagnosis at 6 months, 1 year,
2 years, and 3 years is 100 %, 84 %, 39 %, and 26 %.
The single patient who had local disease and under-
went a pancreaticoduodenectomy with subsequent de-
velopment of metastatic disease had an overall survival
of 50 months from diagnosis of metastases, however
survived only 4 months from initial TARE. Two of the
five patients who were treated with SBRT for their
primary lesion are still alive at the time of assessment.
The median overall survival and survival from TARE are
18 months (range 11 months – not reached) and
9.4 months (range 3 months – not reached), respectively.
Follow up imaging was available for 13 patients (Fig. 2).
Local partial response (PR), stable disease (SD), and dis-
ease progression (PD) based on RECIST criteria were
seen in four (31 %), five (38 %) and four (31 %) patients,
respectively. The average local and systemic progression-
free survival (PFS) was 4.9 and 3.4 months, respectively
(Table 3).
Liver function tests (AST, ALT, alkaline phosphatase,
and total bilirubin) were available at one month post-
TARE for 15 patients, and three months post TARE for
12 patients. No treatment related grade 3 or higher hep-
atic dysfunction was demonstrated at 1 month, although
one patient developed grade 3 elevation of total bilirubin
at three months. No grade 4 or 5 elevation of any liver
function tests was seen at three months. One patient
died 40 days following treatment, presumably due to dis-
ease progression. Another patient developed transient
radiation cholecystitis and hepatitis following therapy
but his liver enzyme levels returned to baseline after
one month.
Discussion
Trans-arterial radioembolization has been used with in-
creasing frequency to treat a variety of liver dominant
secondary cancers. Given the limited efficacy of systemic
therapy alone for patients with metastatic pancreatic
adenocarcinoma, we have incorporated TARE with the
hope of better managing the outcome of patients.
There is currently limited published experience re-
garding the incorporation of liver-directed therapy for
management of metastatic PDAC. Azizi and colleagues
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Right lobe 1.15 GBq (range 0.73 – 1.64)
Left lobe 0.74 GBq (range 0.40 – 1.04)
Administered activity
Right lobe 1.00 GBq (range 0.55 – 1.74)
Left lobe 0.64 GBq (range 0.35 – 0.91)
Lobar dose
Right lobe 46 Gy (30 – 65)
Left lobe 54 Gy (32 – 86)
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(2011) published their findings on the role of repetitive
trans-arterial chemoembolization (TACE) for the
management of metastatic pancreatic adenocarcinoma
[19]. Thirty-two patients underwent conventional TACE
(cTACE) using a triple chemotherapeutic regimen of
mitomycin C, cisplatin, and gemcitabine administered as
an emulsification with Lipiodol followed by embolization
with 200–450 micrometer microspheres. Based on
RECIST criteria, the disease control rate in this treated
cohort was 81 % (PR 9 %, SD 72 %), and the median
overall survival was 16 months.
There are two published retrospective studies asses-
sing the efficacy of TARE in the management of a PDAC
patient population. First, Cao et al. (2010) retrospectively
evaluated seven patients with liver metastases from
pancreatic adenocarcinoma [20]. Follow-up imaging was
available for five patients. Two patients demonstrated
PR, one had SD, and two had PD following TARE.
Survival data was not presented but it was noted that
one patient was still alive 15 months after treatment.
No adverse events were noted for any of the treated
patients.
More recently, Michl et al. (2014) published their
experience with TARE as a treatment for 19 patients with
metastatic pancreatic adenocarcinoma [21]. Twelve pa-
tients had liver-dominant metastatic disease, and seven
had liver-only disease at the time of TARE. The majority
(84 %) had received prior palliative chemotherapy. At
Fig. 1 Median overall survival (a) Kaplan-Meier curve demonstrating median overall survival from diagnosis of metastatic pancreatic ductal
adenocarcinoma (b) Kaplan-Meier curve demonstrating median overall survival from TARE
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first follow-up, 64 % of patients demonstrated anti-
tumor response in the liver, and 36 % demonstrated
progression of disease. Following TARE, median over-
all survival from time of initial diagnosis was
9.0 months in the patients with liver-dominant meta-
static disease, and 18.9 months in patients that had
liver-only disease. One patient experienced treatment-
related gastric ulceration requiring gastrectomy. Two
patients developed hepatic abscesses following treat-
ment, and two others developed signs of radioemboli-
zation induced liver dysfunction (REILD).
As opposed to the studies by Michl and Cao, we
utilized a novel strategy of incorporating TARE with
systemic chemotherapy, as opposed to using TARE as a
salvage therapy. A short break of systemic therapy was
added during time of TARE to reduce risks from radio-
sensitization and/or patient fatigue with an average of
40 days between cycles. Despite concurrent treatment of
patients with systemic chemotherapy—eight of who
received gemcitabine-based therapy, we encountered
minimal treatment-related hepatotoxicity with only one
patient developed grade 3 elevation of total bilirubin
three months post-TARE.
Fig. 2 Pre, intra, and post TARE imaging (a) Pre-procedural CT
demonstrating a segment 4 metastatic pancreatic adenocarcinoma
measuring 4.4 x 2.2 cm (b) Hepatic angiogram demonstrating
enhancing segment 4 mass with aberrant arterial vasculature (c)
3 month post procedure CT demonstrating PR to TARE with lesion
now measuring 2.8 x 1.8 cm














1 SD 1 SD 1
2 PD 3 PD 3
3 PR 3 PR 3
4 PR 5 PR 5
5 N/A N/A
6 SD 1.5 SD 1.5
7 SD 10 SD 6
8 PD 3 PD 3
9 SD 8 SD 4
10 PD 3 PD 3
11 SD 6 SD 3
12 PR 2 PD 2
13 PD 2 PD 2
14 PR 2 PR 2
15 N/A N/A
16 N/A N/A
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The retrospective nature of our study means that it
has inherent weaknesses. The sample size is small – data
is reported from only 16 treated patients – and lacks a
control group for comparison. Furthermore, given the
selection criteria for treatment, patients with rapidly
progressing disease were excluded from the study, lead-
ing to potential selection bias. The findings from our
study, however, with a median overall survival of
22.0 months from diagnosis and 12.5 months from
TARE, compares favorably with the established overall
median survival of 8.5–11 months demonstrated with
systemic chemotherapy alone for patients with meta-
static pancreatic cancer [5, 6]. The apparent safety and
improved efficacy of our treatment support the strategy
of incorporating TARE with concurrent chemotherapy
in the treatment of patients with liver-dominant meta-
static pancreatic ductal adenocarcinoma. Further pro-
spective evaluation of the efficacy of this treatment
strategy is warranted.
Conclusions
Incorporation of Yttrium-90 radioembolization to stand-
ard chemotherapy appears to be safe may improve
patient outcomes. Prospective evaluations are warranted
to validate our findings.
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